Moreover, treatment of SMARCAL1‐deficient B16/F10 tumors with anti‐PD‐L1 antibody or anti‐CTLA‐4 antibody significantly reduced tumor growth and improved animal survival. This evidence concerns the gene SMARCAL1 and neoplasm.